Taken together, these insights have clinical implications as they suggest that tumors with certain defects in DNA repair mechanisms may be selectively sensitive to NAMPT inhibitors, and that rational combinations with chemotherapies may enhance the efficacy of this class of agents, particularly in selected tumor types. The gene discussed is NAMPT; the disease is neoplasm.